2018
The optimal timing of hepatitis C therapy in liver transplant‐eligible patients: Cost‐effectiveness analysis of new opportunities
Cortesi P, Belli L, Facchetti R, Mazzarelli C, Perricone G, De Nicola S, Cesana G, Duvoux C, Mantovani L, Strazzabosco M, Association T. The optimal timing of hepatitis C therapy in liver transplant‐eligible patients: Cost‐effectiveness analysis of new opportunities. Journal Of Viral Hepatitis 2018, 25: 791-801. PMID: 29406608, DOI: 10.1111/jvh.12877.Peer-Reviewed Original ResearchConceptsHepatocellular carcinomaDCC patientsTreatment strategiesIntestine Transplant AssociationProgression of HCVTransplant-eligible patientsHepatitis C therapyTransplant-related factorsCohort of patientsTime of transplantationDecision analytical modelCost-effectiveness analysisDAA effectivenessDAA treatmentEuropean LiverHCC presencePre-LTMELD scoreC therapyCirrhotic patientsDisease recurrenceTransplant centersSpecific regimenTransplant AssociationPatient level
2016
Effective but costly: How to tackle difficult trade‐offs in evaluating health improving technologies in liver diseases
Mantovani LG, Cortesi PA, Strazzabosco M. Effective but costly: How to tackle difficult trade‐offs in evaluating health improving technologies in liver diseases. Hepatology 2016, 64: 1331-1342. PMID: 26926906, DOI: 10.1002/hep.28527.Peer-Reviewed Original ResearchConceptsHealth economic evaluationsEconomic evaluationAlternative health care interventionsDecision analytical modelingCost-effectiveness analysisHealth economic analysisDecision analytical modelDecision analytic modelHealth care interventionsEconomic analysisEconomic sustainabilityHealth care costsBudget impactDecision makersMedical innovationCare costsSocioeconomic contextSustainabilityCare interventionsFair accessMarketMakersAnalytical toolsInnovationCurrent context